Drug glossary Drug

Bupivacaine Marcaine, Sensorcaine, Exparel

A drug being studied in colorectal cancer trials. It appears in 2 clinical trials.

Topical Voltage-gated sodium channels
See its trials
United States FDA approved Since 1963
European Union No data
Spain No data

What it is

Bupivacaine is a long-acting local anesthetic from the amide class that is used in colorectal cancer surgery to provide extended post-operative pain control. In CRC treatment, it serves as a supportive care medication to manage surgical pain following colectomy and other colorectal procedures. The drug is particularly valuable in enhanced recovery protocols where minimizing opioid use and facilitating early mobilization are key goals.

How it works

Bupivacaine blocks voltage-gated sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses that transmit pain signals. This sodium channel blockade occurs at the site of injection, providing localized anesthesia that can last 8-12 hours depending on the formulation and injection site.

Molecular targets

Common side effects

Injection site reactionsNumbnessTinglingDizzinessNauseaVomitingHypotensionBradycardia

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.